LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.14 -4.2

Buy Sell

Overview

Share price change

24h

Current

Min

1.12

Max

1.17

Key metrics
By Trading Economics
Income	17M -26M
Employees	171
EBITDA	19M -23M

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	-31M 72M
Previous open	5.34
Previous close	1.14

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lut 2026, 23:47 UTC

Hot Stocks

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 lut 2026, 22:59 UTC

Earnings

Acquisitions, Mergers, Takeovers

Grab Holdings to Buy U.S.-Based Stash Financial

11 lut 2026, 23:54 UTC

Earnings

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 lut 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11 lut 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 lut 2026, 23:49 UTC

Earnings

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 lut 2026, 23:45 UTC

Earnings

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 lut 2026, 23:42 UTC

Earnings

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 lut 2026, 23:41 UTC

Earnings

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 lut 2026, 23:40 UTC

Earnings

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 lut 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 lut 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 lut 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 lut 2026, 22:59 UTC

Earnings

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 lut 2026, 22:59 UTC

Earnings

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 lut 2026, 22:59 UTC

Earnings

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 lut 2026, 22:58 UTC

Earnings

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 lut 2026, 22:57 UTC

Earnings

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 lut 2026, 22:54 UTC

Earnings

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 lut 2026, 22:53 UTC

Earnings

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 lut 2026, 22:47 UTC

Earnings

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 lut 2026, 22:47 UTC

Earnings

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 lut 2026, 22:23 UTC

Earnings

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 lut 2026, 22:22 UTC

Earnings

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 lut 2026, 22:22 UTC

Earnings

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 lut 2026, 22:19 UTC

Earnings

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 lut 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 lut 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 lut 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 lut 2026, 22:16 UTC

Earnings

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Rating Consensus

By TipRanks

Sell

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.